From Bench to Bed: Molecular Markers for Clinical Use
Biomarkers in Early-Stage Colorectal Cancer: Ready for Prime Time?Church D.a · Midgley R.b · Kerr D.b
aOxford Cancer Centre and bDepartment of Clinical Pharmacology, University of Oxford, Oxford, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background/Aims: During the last two decades, hundreds of reports have detailed putative prognostic and predictive biomarkers for colorectal cancer (CRC). However, the majority of these studies have been small and retrospective, reporting results that are highly likely to represent false positives. Consequently, their relevance to clinical practice requires definition. Methods: Review of published literature on CRC biomarkers, focusing on early-stage disease. Results: Although most putative biomarkers have failed to be validated in subsequent studies, level I evidence now indicates that tumour microsatellite instability can be used to identify a cohort of patients with stage IIA disease at low risk of relapse who can be spared adjuvant chemotherapy. Emerging data suggest that gene expression arrays may have a role in selecting patients with stage IIA disease and mismatch repair-proficient tumours for chemotherapy following tumour resection. Conclusion: Despite the profusion of biomarker literature, only mismatch repair status can be recommended as routine in current clinical practice. High-quality, adequately powered studies are essential to accurately define the utility of existing and putative biomarkers, and to support their rational application in the clinic.
© 2012 S. Karger AG, Basel
- Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–2917.
- Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al; Quasar Collaborative Group: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020–2029.
- O’Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420–1425.
- Midgley RS, Church D, Kerr DJ: The emergence of ‘omics for the management of colorectal cancer. Curr Opin Oncol 2011;23:410–414.
- Anwar S, Frayling IM, Scott NA, Carlson GL: Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 2004;91:1275–1291.
- Munro AJ, Lain S, Lane DP: P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434–444.
- Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446–1452.
- Walther A, Houlston R, Tomlinson I: Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008;57:941–950.
- Lee AJX, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, et al: Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011;71:1858–1870.
- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–532.
- Popat S, Houlston RS: A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005;41:2060–2070.
- Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11–22.
- Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103–2114.
- Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA: Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011;154:37–49.
- Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091–2096.
- Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962–972.
- Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466–474.
- Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, et al: Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995;55:5548–5550.
- Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM, et al: Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 1996;14:255–257.
- Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967–969.
- Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
- Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870–6875.
- Risio M, Reato G, di Celle PF, Fizzotti M, Rossini FP, Foà R: Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. Cancer Res 1996;56:5470–5474.
- Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Påhlman L, et al: Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 1999;81:190–193.
- Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, et al: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002;360:1381–1391.
- Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295–1303.
- Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196–1206.
- Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, et al: Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer – a study of CALGB 9581 and 89803. J Clin Oncol 2011;29:3153–3162.
- Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011;103:863–875.
- Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219–3226.
- Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609–618.
- Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123–131.
- Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247–257.
- Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126:394–401.
- Storojeva I, Boulay J-L, Heinimann K, Ballabeni P, Terracciano L, Laffer U, et al: Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep 2005;14:241–249.
- Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E: Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 2010;46:2788–2798.
- Guetz Des G, Schischmanoff O, Nicolas P, Perret G-Y, Morere J-F, Uzzan B: Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009;45:1890–1896.
- Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, et al: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767–772.
- Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al: Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 2004;22:1564–1571.
- Jiang Y, Casey G, Lavery IC, Zhang Y, Talantov D, Martin-McGreevy M, et al: Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn 2008;10:346–354.
- Barrier A, Lemoine A, Boelle P-Y, Tse C, Brault D, Chiappini F, et al: Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005;24:6155–6164.
- Barrier A, Boelle P-Y, Roser F, Gregg J, Tse C, Brault D, et al: Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006;24:4685–4691.
- Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al: Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005;23:3526–3535.
- Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17–24.
- O’Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937–3944.
Kerr DG, Quirke R, Watson P, et al: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;27(15s suppl):abstract 4000.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.